Anti-HDL lipid parameter increased rather than decreased in CHD patients receiving statin therapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • HDL-apoCIII, which is associated wth congestive heart disease, was elevated in patients with CHD following statin therapy while other key lipid parameters were reduced

Study Design

  • Hospital-based observational study to investigate the association between HDL-apoCIII and congestive heart disease (CHD) and the effect of statin therapy on such levels in patients with CHD
  • Study population: 80 non-CHD patients and 120 CHD patients without statin treatment
  • All CHD patients received statin therapy and 63 of them were followed-up after 3 months of statin therapy

Key Results

  • Significantly higher HDL-apoCIII in patients with CHD vs patients without (P<.05)
  • Significantly elevated total plasma apoCIII in patients with CHD following statin therapy, whereas TC, LDL-C, and apoB were significantly decreased

Why This Matters

  • ApoCIII is believed to impair the anti-atherogenic properties of HDL-C in patients with CHD
  • The effects of statin therapy on apoCIII have remained unclear